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We conducted a retrospective, multicenter study evaluating the safety of discontinuing maintenance therapy for
cryptococcal meningitis after immune reconstitution. Inclusion criteria were a previous definitive diagnosis of
cryptococcal meningitis, a CD4 cell count of 1100 cells/mL while receiving highly active antiretroviral therapy
(HAART), and the subsequent discontinuation of maintenance therapy for cryptococcal meningitis. The primary
end point was relapse of cryptococcal disease. As of July 2002, 100 patients were enrolled. When maintenance
therapy was discontinued, the median CD4 cell count was 259 cells/mL and the median plasma virus load was
!2.30 log10 copies/mL, and serum cryptococcal antigen was undetectable in 56 patients. During a median follow-
up period of 28.4 months (range, 6.7–64.5; 262 person-years), 4 events were observed (incidence, 1.53 events per
100 person-years; 95% confidence interval, 0.42–3.92). Three of these patients had a CD4 cell count of 1100 cells/
mL and a positive serum cryptococcal antigen test result during the recurrent episode. In conclusion, discontin-
uation of maintenance therapy for cryptococcal meningitis is safe if the CD4 cell count increases to 1100 cells/
mL while receiving HAART. Recurrent cryptococcal infection should be suspected in patients whose serum
cryptococcal antigen test results revert back to positive after discontinuation of maintenance therapy.
The advent of HAART has deeply affected not only the
incidence of opportunistic infections, but also the rec-
ommendations for primary and secondary prophylaxis
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[1, 2]. Actually, it is possible to discontinue prophylactic
regimens if the CD4 cell count increases to a value
higher than that considered to indicate risk for the
development of opportunistic infections before the
availability of HAART [3–18]. The management of
AIDS-associated cryptococcal meningitis (CM) likely
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does not differ significantly from management of other AIDS-
associated opportunistic infections, and HAART may, in fact,
diminish the risk of recurrence once the infection has been
adequately treated.
We studied persons with a diagnosis of CM whose CD4 count
increased to 1100 cells/mL while receiving HAART and who
discontinued maintenance therapy to determine whether main-
tenance therapy for CM can be safely discontinued for patients
with presumed immune reconstitution.
SUBJECTS, MATERIALS, AND METHODS
This is a multicenter retrospective study on the discontinuation
of maintenance therapy for CM in subjects treated with HAART
who had CD4 cell counts of 1100 cells/mL before discontinuing
antifungal therapy. CD4 cell counts were determined and
plasma virus load assays were performed at each site. Cryp-
tococcal antigens were detected in serum and CSF samples
using commercially available latex agglutination systems. Case
records of patients observed in 21 centers (listed in the study
group section at the end of the text) were evaluated. Some of
the cases reported in this article were previously reported [4,
17].
Inclusion and exclusion criteria. We included patients
with HIV-1 infection who had a definitive diagnosis of 1
episode of CM when their CD4 cell count was !100 cells/mL,
who received maintenance therapy, and who discontinued
maintenance therapy after they attained a CD4 cell count of
1100 cells/mL while receiving HAART. A diagnosis of CM was
considered definitive if Cryptococcus neoformans was isolated
from a CSF specimen or if there was a positive result of a CSF
cryptococcal antigen titer or CSF india ink preparation study.
Maintenance therapy was defined as treatment with any drug
with known activity against C. neoformans at recommended
standard doses and included fluconazole, itraconazole, and am-
photericin B. HAART was defined as a combination of 3
antiretroviral agents. The decision to discontinue maintenance
therapy was either an independent decision made by the patient
or resulted from consultation between individual patients and
their physicians.
End points. The primary end points of the study were a
confirmed diagnosis of recurrence of CM, any evidence of cryp-
tococcal disease, or death. Secondary end points were any new
AIDS-defining illness [19], a decrease in the CD4 cell count to
!100 cells/mL, and reinstitution of maintenance therapy.
Statistical analysis. All participants who underwent 1
follow-up evaluation after discontinuation of maintenance
therapy were included in the analysis. The duration of follow-
up was measured from the time of discontinuation to the date
of the last visit or the date that a primary end point was reached.
Incidences of CM and death related to this opportunistic in-
fection were calculated for the period in which the patients
were not receiving maintenance therapy. Events were assumed
to have a Poisson distribution, and exact 95% CIs were cal-
culated for the incidence of end points. SAS software, version
8.1 (SAS Institute), was used for statistical analysis.
RESULTS
Characteristics of Patients
A total of 100 patients were included in the study. The median
duration of follow-up was 26.5 months (range, 12.7–76.8
months). The number of patients enrolled at each country and
selected epidemiological and clinical characteristics of the study
participants are shown in table 1. The median time from the
first diagnosis of CM to the end of the observation period was
68.7 months (range, 23.9–113.7 months). The median duration
of HAART before discontinuation of maintenance therapy was
26.1 months (range, 0.4–56.2 months). The median duration
of maintenance therapy was 33.0 months (range, 2.0–90.7
months). The median time from the first CD4 cell count of
1100 cells/mL to the discontinuation of maintenance therapy
was 1 month (range, 0.4–40.4 months). In fact, clinicians or
patients themselves decided to discontinue maintenance ther-
apy for 54 patients (54.0%) within 1 month after the first CD4
cell count of 1100 cells/mL, whereas, for the remaining 46 pa-
tients (46.0%), the median time was 13.7 months.
CD4 Cell Count, Plasma Virus Load, and Detection
of Cryptococcal Antigen
Viroimmunological parameters and serum cryptococcal antigen
data are shown in table 2. Twenty-five (61.0%) of the 41 patients
with a positive serum cryptococcal antigen test result at time
of antifungal therapy discontinuation continued to have pos-
itive results during the follow-up period (median titer, 1:128;
range, 1:4–1:8192). Five (8.9%) of the 56 patients with a neg-
ative serum cryptococcal antigen result at the time of discon-
tinuation had positive results during the follow-up period (ti-
ters were 1:512, 1:128, and 1:32 for 1 patient each and 1:16
for 2 patients). Maintenance therapy for CM was not restarted
on the basis of the titer of serum cryptococcal antigen alone.
Incidence of Primary End Points
No events occurred during a median period of 26.1 months
(220 person-years) when patients were taking both HAART
and maintenance therapy for CM. The incidence during that
period was 0% (95% CI, 0–1.67 cases per 100 person-years).
After discontinuation of maintenance therapy, during a period
of observation of 262 person-years (median, 28.4 months;
range, 6.7–64.5 months), 2 cases of CM and 2 extrameningeal
cryptococcal infections were diagnosed. The incidence of re-
lapse of cryptococcal infection was 1.53 cases per 100 person-
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Table 1. Demographic and clinical characteristics of 100 HIV-
infected adults who were receiving HAART and who discontinued
maintenance therapy for cryptococcal meningitis.
Characteristic Value
Country of origin
Italy 35 (35.0)
Spain 21 (21.0)
Argentina 16 (16.0)
Great Britain 16 (16.0)
France 3 (3.0)
United States 9 (9.0)
Sex
Male 84 (84.0)
Female 16 (16.0)
HIV exposure group
Injection drug users 34 (34.0)
Men who have sex with men 40 (40.0)
Heterosexuals 19 (19.0)
Other 7 (7.0)
Age at first diagnosis of cryptococcal meningitis,
median years (range) 33.6 (15.2–56.7)
Maintenance therapy for cryptococcal meningitis
Fluconazole 93 (93.0)
Itraconazole 4 (4.0)
Liposomal amphotericin B 3 (3.0)
Relapse of cryptococcal meningitis before HAART 12 (12.0)
Time from last episode of cryptococcal meningitis to
HAART initiation, median months (range) 6.62 (0.0–49.0)
Antiretroviral therapy naive at HAART initiation 39 (39.0)
Antiretroviral therapy received at the time of CD4 cell
count of 1100 cells/mL
Indinavir 39 (39.0)
Nelfinavir 14 (14.0)
Ritonavir 2 (2.0)
Nevirapine 17 (17.0)
Efavirenz plus 2 NRTIs 12 (12.0)
Ritonavir-lopinavir plus 2 NRTIs 9 (9.0)
Amprenavir plus 2 NRTIs 1 (1.0)
Abacavir plus 2 NRTIs 3 (3.0)
Saquinavir plus 2 NRTIs 3 (3.0)
Time from last episode of cryptococcal meningitis to
discontinuation of maintenance therapy, median
months (range) 36.7 (4.4–91.6)
Time from HAART initiation to discontinuation of mainte-
nance therapy, median months (range) 26.1 (3.2–56.2)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
years (95% CI, 0.42–3.92 cases per 100 person-years; ,Pp .08
compared with the period when patients were receiving main-
tenance therapy).
Case Reports
Patient 1. A 39-year-old man discontinued maintenance
therapy for CM and primary PCP prophylaxis 42 months after
commencing HAART and 58 months after diagnosis of CM.
At the time that prophylaxis was discontinued (16 months after
a CD4 cell count of 1100 cells/mL was attained), the CD4 cell
count was 185 cells/mL (13% of the total lymphocyte count),
the plasma virus load was !200 copies/mL, and the serum
cryptococcal antigen test result was negative. Two months later,
he was admitted to the hospital because of fever and dyspnea.
A chest radiograph revealed bilateral interstitial infiltrates. Se-
rum and CSF cryptococcal antigen titers were 1:2048, but the
results of blood and CSF cultures were negative. CSF chemistry
findings were normal. Examination of a bronchoalveolar lavage
(BAL) specimen failed to recover any pathogens. The CD4 cell
count was 136 cells/mL, and the plasma virus load was 7810
copies/mL. The patient was successfully cured with a full course
of trimethoprim-sulfamethoxazole and amphotericin B.
Patient 2. A 32-year-old man discontinued maintenance
therapy for CM 12 months after HAART was commenced, 26
months after CM was diagnosed, and 9 months after a CD4
cell count of 1100 cells/mL was attained. His CD4 cell count
was 405 cells/mL (25% of the total lymphocyte count), his
plasma virus load was !200 copies/mL, and the serum cryp-
tococcal antigen test result was negative. Eleven months after
stopping maintenance therapy, the patient had an elevated lac-
tose dehydrogenase level (1019 U/L). He was asymptomatic.
The CD4 cell count was 465 cells/mL (31% of the total lym-
phocyte count), and the plasma virus load was !200 copies/
mL. A CT scan of the body revealed a splenic mass. The patient
had several transient motor deficits mimicking ischemic attacks.
MRI of the brain revealed small nodules (diameter, 1–2 mm)
on the cranial floor. CSF chemistry and pressure findings were
normal. The results of CSF and serum cryptococcal antigen
tests were negative. Results of blood, BAL, and CSF cultures
were negative. A diagnostic splenectomy was performed, and
the histopathological diagnosis revealed C. neoformans. Culture
was not performed. The patient was successfully treated with
liposomal amphotericin B.
Patient 3. A 43-year-old man discontinued maintenance
therapy for CM 9 months after HAART was started, 14 months
after CM was diagnosed, and 8 months after a CD4 cell count
of 1100 cells/mL was attained. The patient’s CD4 cell count was
236 cells/mL, his plasma virus load was 122,000 copies/mL, and
a serum cryptococcal antigen test was not performed. One year
later, the patient was admitted to the hospital with weakness,
stupor, and headache. CT of the brain revealed multiple ring-
enhancing lesions with surrounding edema. A CSF examination
revealed only a protein level of 250 mg/mL and a lymphocyte
count of 6 lymphocytes/mL. The CSF cryptococcal antigen titer
was 1:512, and CSF culture yielded C. neoformans. The patient’s
CD4 cell count was 46 cells/mL (13% of the total lymphocyte
count), and his plasma virus load was !200 copies/mL. The
patient was treated with amphotericin B, sulfadiazine, and pyr-
Table 2. Viroimmunological parameters and detection of cryptococcal antigen in patients who discontinued maintenance therapy for cryptococcal meningitis.
Characteristic
Recurrent cryptococcal meningitis
Cryptococcal antigen detected at
discontinuation of maintenance therapy Cryptococcal antigen detected at last visit
No
(n p 96)
Yes
(n p 4)
Negative
(n p 56)
Positive
(n p 41)
Negative
(n p 67)
Positive
(n p 30)
Interval since last episode of cryptococcosis, months 68.76 (23.89–113.71) 41.66 (41.23–92.88) 71.85 (26.41–113.71) 66.17 (23.89–97.77) 70.83 (26.41–113.71) 62.62 (23.89–95.08)
Duration of HAART before discontinuation
of maintenance therapy, months 26.15 (3.20–56.18) 10.97 (9.23–41.56) 24.85 (3.40–55.33) 26.64 (3.55–56.18) 25.00 (3.33–55.33) 28.22 (3.25–56.18)
At discontinuation of maintenance therapy
CD4 cell count, cells/mL 260 (100–1231) 236 (185–279) 274 (100–668) 239 (102–1231) 260 (100–668) 260 (100–1231)
Plasma HIV load, log10 copies/mL 2.30 (1.60–6.30) 2.30 (1.70–5.09) 2.30 (1.60–5.27) 1.90 (1.60–6.30) 2.30 (1.60–6.00) 2.30 (1.60–6.34)
At last visit
CD4 cell count, cells/mL 372 (7–1510) …a 400 (7–837) 321 (8–1510) 384 (7–837) 283 (24–1510)
Plasma HIV load, log10 copies/mL (range) 1.76 (1.30–5.67) 2.30 (1.70–2.30) 1.90 (1.30–5.67) 1.88 (1.60–5.49) 1.90 (1.60–5.67) 1.70 (1.30–5.49)
NOTE. Data are median (range).
a The individual values for the 4 patients who experienced a recurrent episode of cryptococcosis were 13, 465, 46, and 536 cells/mL.
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imethamine. The patient died of respiratory failure 4 months
after hospital admission. An autopsy was not performed.
Patient 4. A 31-year-old man discontinued maintenance
therapy for CM 20 months after a CD4 cell count of 1100 cells/
mL was attained and 31 months after CM was diagnosed. The
patient’s CD4 cell count was 536 cells/mL (13.2% of the total
lymphocyte count), his plasma virus load was !50 copies/mL,
and the results of a serum cryptococcal antigen test were neg-
ative. One month later, he had fever, cough, and headache. The
findings of a physical examination were normal. The serum
cryptococcal antigen titer result became positive (titer, 1:256),
but blood and CSF culture results were negative. CT of the
body revealed mediastinal, periaortic, and abdominal lymph
nodes. Histological examination of a lymph node specimen
revealed the presence of C. neoformans. Culture was not per-
formed. The patient was successfully treated with oral
fluconazole.
Secondary End Points
Apart from those described above, no other deaths or AIDS-
related events occurred during the observation period. Five
patients (5%) had a confirmed CD4 cell count of !100 cells/
mL; for 4 of these patients, the CD4 cell count was attributed
to discontinuation of antiretroviral treatment. One of the pa-
tients developed CM, whereas maintenance therapy for CM
was reinitiated for the remaining 4 patients.
DISCUSSION
This study demonstrates that persons with CM taking HAART
have a lower risk of relapse when the CD4 cell count increases
to 1100 cells/mL, even in the absence of antifungal maintenance
therapy. For comparison, in the pre-HAART era, without an-
tifungal maintenance therapy, 50%–60% of the patients ex-
perienced a relapse of this opportunistic infection during 1 year
of follow-up [20–21]. However, in the present study, only 4
events in 262 person-years occurred. This suggests that the
observed CD4 cell recovery during HAART is associated with
protection against recurrent cryptococcal meningitis and that
it appears to be safe to withdraw maintenance therapy for cryp-
tococcosis in HIV-infected individuals who have presumed im-
mune reconstitution while receiving HAART.
Of note, 3 of 4 patients with recurrent cases had a negative
serum cryptococcal antigen test result at the time of discon-
tinuation of antifungal therapy. The cryptococcal antigen test
is a sensitive and relatively specific indicator of CNS crypto-
coccosis. Active cryptococcal infection may be present in some
patients with positive cryptococcal antigen test results but neg-
ative fungal culture results. Recent recommendations have been
to presumptively treat any HIV-infected person who has a pos-
itive cryptococcal antigen test result and a negative culture
result, regardless of the presence or absence of clinical symp-
toms [22]. There have been several studies noting the lack of
clinical utility in serial monitoring of serum and/or CSF cryp-
tococcal antigen, but none of the studies have ever addressed
the scenario of an antigen test result becoming negative and
later turning positive [23–26]. In the absence of such data, it
would seem prudent to consider this to be either a recurrent
disease or reinfection with C. neoformans. We are unaware of
any other reports describing the reversion of a negative serum
cryptococcal antigen test result to a positive result. This was
the case for 2 of the patients who had recurrent episodes of
cryptococcal infection. This is a completely new scenario—in
fact, before the HAART era, it was common to say, “semel
Cryptococcus, semper Cryptococcus” (i.e., “once you have had
Cryptococcus infection, you will always have it”). After the ad-
vent of HAART, and on the basis of the results of the present
study, one could conclude that C. neoformans infection may
be completely eradicated or remain latent in most patients, but
it may relapse or a patient may develop a new infection. Our
study leads us to reinforce the indication for close monitoring
of the CD4 cell count in patients who discontinue maintenance
therapy. Indeed, patient 3 had a rapid and unpredictable de-
crease in the CD4 cell count, despite having an undetectable
plasma virus load, which, in the absence of prophylactic reg-
imens, allowed the onset of opportunistic infection.
After the advent of the HAART era, some observational and
randomized trials [27, 28] reported the onset of opportunistic
infections in patients with CD4 cell counts greater than what
is considered at risk. This is also the case for 3 of the 4 patients
we describe who had a relapse of CM.
When interpreting the results of this study, 2 main limitations
should be considered. First, because of the retrospective, ob-
servational nature of the study, we cannot exclude the possi-
bility that persons with more-stable disease were overrepre-
sented. Because the present study, which had a large sample
size, demonstrated that recurrent episodes of CM are possible,
a large, randomized trial from countries where it is endemic is
warranted. Nevertheless, a randomized trial conducted in Thai-
land with a small sample size reported the absence of any
recurrent episodes in the discontinuation arm after 1 year of
follow-up [18]. The second limit to our study is that it does
not directly address the issue of when maintenance therapy for
CM can safely be discontinued. The most recent guidelines
suggest to wait until 3–6 months after the first CD4 cell count
of 1100 cells/mL is attained [29]. In the present study, one-half
of the patients discontinued therapy soon after the CD4 cell
count increased to 1100 cells/mL, and none of these patients
had a recurrent episode. On the contrary, all events occurred
in patients who discontinued antifungal maintenance therapy
after they had had a CD4 cell count of 1100 cells/mL for 6
months. A possible explanation is that these patients may have
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had specific immune defects against C. neoformans that are not
routinely assessed in clinical laboratories [30]. Another possi-
bility that we cannot exclude is reinfection.
In conclusion, the present study indicates that it may be
considered safe to discontinue maintenance therapy for CM
after HAART and a CD4 count 1100 cells/mL. Nevertheless,
patients should be carefully monitored for a sudden decrease
in the CD4 cell count in order to reintroduce prophylactic
regimens. Moreover, it may be of utility to measure a serum
cryptococcal antigen value at the time that antifungal therapy
is discontinued, and it may be prudent to empirically treat
patients whose negative results revert to positive. Finally, pa-
tients should receive clear advice regarding this risk and should
be monitored closely for the onset of any new symptoms, such
as headache or fever.
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